Clinical study of omeprazole and rabeprazole quadruple therapy on Helicobacter pylori associated peptic ulcer
10.7501/j.issn.1674-6376.2017.06.022
- VernacularTitle:雷贝拉唑与奥美拉唑四联疗法治疗幽门螺杆菌相关性消化性溃疡的疗效比较
- Author:
Yanhong ZHU
;
Yingjie WU
;
Chunli ZHANG
- Keywords:
Rabeprazole;
Omeprazole;
helicobacter pylori;
peptic ulcer
- From:
Drug Evaluation Research
2017;40(6):836-839
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the clinical application value of omeprazole and rabeprazole quadruple therapy on Helicobacter pylori associated peptic ulcer.Methods 360 patients with Helicobacter pylori associated peptic ulcer were selected.They were divided into two groups randomly.The rabeprazole group (180 cases) was treated with rabeprazole with quadruple therapy based,omeprazole group (180 cases) was treated with omeprazole quadruple therapy of short acting as the foundation,to observe and record the two groups of patients with clinical curative effect,the healing rate of ulcer,Helicobacter pylori eradication rate,histopathology and treatment of gastric mucosa during adverse reaction condition.Results The cure rate of rabeprazole group was significantly higher than that of omeprazole group (P ＜ 0.05).Compared the two groups before treatment,upper abdominal pain,abdominal discomfort,belching symptoms,no significant difference,the two groups after treatment in patients with upper abdominal pain,abdominal discomfort and belching percentage of patients decreased,and Rebela was the proportion of patients with lower group (P ＜ 0.05).After treatment,the rabeprazole group of ulcer healing rate 90.5％ (163/180),Helicobacter pylori eradication rate was 87.8％ (158/180),omeprazole group of ulcer healing rate was 70.5％ (127/180),Helicobacter pylori eradication rate was 72.2％ (130/180).The rabeprazole group of the healing rate of ulcer and Helicobacter pylori eradication rate were higher (P ＜ 0.05).Before treatment,there was no significant difference on gastric mucosal histopathological score between two groups.After treatment,two groups of gastric mucosa pathological score were decreased (P ＜ 0.05),no difference between the two groups.During the treatment,there was no significant difference on adverse reactions between two groups.Conclusion Rabeprazole with short acting quadruple therapy can significantly treat Helicobacter pylori causes,promote gastric mucosa repair,improve the clinical symptoms of peptic ulcer,the medication is safe,it is worthy of clinical use.
